A number of other research analysts have also issued reports on HSIC. BidaskClub raised Henry Schein from a “hold” rating to a “buy” rating in a report on Wednesday, November 27th. TheStreet raised Henry Schein from a “c+” rating to a “b” rating in a report on Monday, October 14th. Zacks Investment Research lowered Henry Schein from a “hold” rating to a “sell” rating and set a $71.00 target price on the stock. in a report on Wednesday, November 6th. Cleveland Research reissued a “hold” rating on shares of Henry Schein in a report on Friday, November 1st. Finally, Piper Jaffray Companies boosted their target price on Henry Schein from $72.00 to $80.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. Henry Schein has an average rating of “Hold” and a consensus target price of $72.17.
NASDAQ:HSIC opened at $69.08 on Tuesday. The firm has a market cap of $10.11 billion, a P/E ratio of 16.73, a PEG ratio of 2.71 and a beta of 0.84. The company has a current ratio of 1.63, a quick ratio of 0.92 and a debt-to-equity ratio of 0.30. The stock’s 50 day simple moving average is $66.15 and its 200-day simple moving average is $65.81. Henry Schein has a 12-month low of $56.58 and a 12-month high of $72.81.
Henry Schein declared that its Board of Directors has authorized a share buyback program on Thursday, October 31st that allows the company to buyback $400.00 million in outstanding shares. This buyback authorization allows the company to buy up to 4.3% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.
In related news, Vice Chairman James P. Breslawski sold 6,856 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $66.96, for a total transaction of $459,077.76. Following the transaction, the insider now owns 242,190 shares of the company’s stock, valued at $16,217,042.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Stanley M. Bergman sold 90,000 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $67.51, for a total value of $6,075,900.00. Following the transaction, the chief executive officer now directly owns 344,554 shares in the company, valued at approximately $23,260,840.54. The disclosure for this sale can be found here. Insiders have sold 123,655 shares of company stock worth $8,373,585 in the last ninety days. 1.06% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Enterprise Financial Services Corp boosted its position in Henry Schein by 101.3% during the third quarter. Enterprise Financial Services Corp now owns 483 shares of the company’s stock worth $31,000 after purchasing an additional 243 shares in the last quarter. Cullen Frost Bankers Inc. purchased a new stake in Henry Schein during the second quarter worth $36,000. Ibex Wealth Advisors purchased a new stake in Henry Schein during the second quarter worth $40,000. Meeder Asset Management Inc. purchased a new stake in Henry Schein during the second quarter worth $59,000. Finally, Rational Advisors LLC boosted its position in Henry Schein by 24.9% during the second quarter. Rational Advisors LLC now owns 903 shares of the company’s stock worth $63,000 after purchasing an additional 180 shares in the last quarter.
About Henry Schein
Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
See Also: Derivative
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.